IMMUNOGEN AND PHARMACEUTICAL COMPOSITION FOR SARS-COV-2 VIRUS, AND USE THEREOF

WIPO Patent Application WO/2022/122036

A1

Disclosed in the present application are an immunogen and a pharmaceutical composition for SARS-CoV-2 virus, and the use thereof. The immunogen comprises at least one of a PreS protein or a full-length S protein, or the immunogen comprises a plurality of structural proteins capable of being assembled to form a SARS-CoV-2 virus-like particle. The immunogen can be used for preparing a vaccine and/or a drug, and has the advantages of a high safety, an ideal immune effect and a long immune persistence.

MU TING (CN)
QIN MIAN (CN)
KLEIN MICHEL (CN)
ZHAO PING (CN)
XU LONG (CN)
WU KE (CN)

PCT/CN2021/137244

June 16, 2022

December 10, 2021

Click for automatic bibliography generation  

BRAVOVAX CO LTD (CN)

C07K14/165; A61K39/215; A61P31/14; C07K19/00; C12N7/01; C12N15/50; C12N15/62; C12N15/861

CN112552380A	2021-03-26
CN112048007A	2020-12-08
CN111088271A	2020-05-01
CN109790548A	2019-05-21
CN111405907A	2020-07-10

HSIEH CHING-LIN, GOLDSMITH JORY A, SCHAUB JEFFREY M, DIVENERE ANDREA M, KUO HUNG-CHE, JAVANMARDI KAMYAB, LE KEVIN C, WRAPP DANIEL,: "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes", SCIENCE, vol. 369, no. 6510, 18 September 2020 (2020-09-18), US , pages 1501 - 1505, XP055780339, ISSN: 0036-8075, DOI: 10.1126/science.abd0826
RUODAN XU, MINGFEI SHI, JING LI, PING SONG, NING LI: "Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, vol. 8, pages 1 - 6, XP055743605, DOI: 10.3389/fbioe.2020.00862

PURPLEVINE INTELLECTUAL PROPERTY (SHENZHEN) CO., LTD. (CN)

View/Download PDF      PDF Help

Previous Patent: COAGULATION FACTOR XIA INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF

Next Patent: DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF